BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34231945)

  • 21. IMRT to escalate the dose to the prostate while treating the pelvic nodes.
    Cavey ML; Bayouth JE; Colman M; Endres EJ; Sanguineti G
    Strahlenther Onkol; 2005 Jul; 181(7):431-41. PubMed ID: 15995836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosimetric advantages and superior treatment delivery efficiency of RapidArc over conventional intensity-modulated radiotherapy in high-risk prostate cancer involving seminal vesicles and pelvic nodes.
    Poon DM; Kam M; Leung CM; Chau R; Wong S; Lee WY; Wong KC; Yu B; Chan A
    Clin Oncol (R Coll Radiol); 2013 Dec; 25(12):706-12. PubMed ID: 23954261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
    Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?
    Sanguineti G; Cavey ML; Endres EJ; Brandon GG; Bayouth JE
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):151-60. PubMed ID: 16198066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daily CT localization for correcting portal errors in the treatment of prostate cancer.
    Lattanzi J; McNeely S; Hanlon A; Das I; Schultheiss TE; Hanks GE
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1079-86. PubMed ID: 9719118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of PTV margins for elective pelvic lymph nodes in online adaptive radiotherapy of prostate cancer patients.
    Brennsæter JA; Dahle TJ; Moi JN; Svanberg IF; Haaland GS; Pilskog S
    Acta Oncol; 2023 Oct; 62(10):1208-1214. PubMed ID: 37682727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer.
    Bayley A; Rosewall T; Craig T; Bristow R; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):477-83. PubMed ID: 19733014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment simulations with a statistical deformable motion model to evaluate margins for multiple targets in radiotherapy for high-risk prostate cancer.
    Thörnqvist S; Hysing LB; Zolnay AG; Söhn M; Hoogeman MS; Muren LP; Bentzen L; Heijmen BJ
    Radiother Oncol; 2013 Dec; 109(3):344-9. PubMed ID: 24183863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer.
    Outaggarts Z; Wegener D; Berger B; Zips D; Paulsen F; Bleif M; Thorwarth D; Alber M; Dohm O; Müller AC
    Acta Oncol; 2020 Aug; 59(8):911-917. PubMed ID: 32436467
    [No Abstract]   [Full Text] [Related]  

  • 30. Optimal image guided radiation therapy strategy for organs at risk sparing in radiotherapy of the prostate including pelvic lymph nodes.
    van Nunen A; van der Toorn PPG; Budiharto TCG; Schuring D
    Radiother Oncol; 2018 Apr; 127(1):68-73. PubMed ID: 29501209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic lymph nodes treated with stereotactic ablative radiotherapy.
    Lyons CA; King RB; Osman SOS; McMahon SJ; O'Sullivan JM; Hounsell AR; Jain S; McGarry CK
    Radiat Oncol; 2017 Aug; 12(1):124. PubMed ID: 28778178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plan robustness of simultaneous integrated boost radiotherapy of prostate and lymph nodes for different image-guidance and delivery techniques.
    Thörnqvist S; Bentzen L; Petersen JB; Hysing LB; Muren LP
    Acta Oncol; 2011 Aug; 50(6):926-34. PubMed ID: 21767193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of optimal PTV margin for patients receiving CBCT-guided prostate IMRT: comparative analysis based on CBCT dose calculation with four different margins.
    Gill SK; Reddy K; Campbell N; Chen C; Pearson D
    J Appl Clin Med Phys; 2015 Nov; 16(6):252–262. PubMed ID: 26699581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plan Selection in Proton Therapy of Locally Advanced Prostate Cancer with Simultaneous Treatment of Multiple Targets.
    Pilskog S; Abal B; Øvrelid KS; Engeseth GM; Ytre-Hauge KS; Hysing LB
    Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):630-638. PubMed ID: 31759076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer.
    Chera BS; Vargas C; Morris CG; Louis D; Flampouri S; Yeung D; Duvvuri S; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):994-1002. PubMed ID: 19619961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alignment focus of daily image guidance for concurrent treatment of prostate and pelvic lymph nodes.
    Ferjani S; Huang G; Shang Q; Stephans KL; Zhong Y; Qi P; Tendulkar RD; Xia P
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):383-9. PubMed ID: 23906929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A quantitative study of IMRT delivery effects in commercial planning systems for the case of oesophagus and prostate tumours.
    Seco J; Clark CH; Evans PM; Webb S
    Br J Radiol; 2006 May; 79(941):401-8. PubMed ID: 16632620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Image-guided IMRT for localized prostate cancer with daily repositioning: inferring the difference between planned dose and delivered dose distribution.
    Arnaud A; Maingon P; Gauthier M; Naudy S; Dumas JL; Martin E; Peignaux-Casasnovas K; Truc G; Bonnetain F; Crehange G
    Phys Med; 2014 Sep; 30(6):669-75. PubMed ID: 24792687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Patient positioning using in-room kV CT for image-guided radiotherapy (IGRT) of prostate cancer].
    Kliton J; Agoston P; Major T; Polgár C
    Magy Onkol; 2012 Sep; 56(3):193-8. PubMed ID: 23008828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosimetric implications of residual seminal vesicle motion in fiducial-guided intensity-modulated radiotherapy for prostate cancer.
    Stenmark MH; Vineberg K; Ten Haken RK; Hamstra DA; Feng M
    Med Dosim; 2012; 37(3):240-4. PubMed ID: 22189029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.